HER family protein expression and activation predicts response to combination T-DM1/pertuzumab in HER2+ patients in the I-SPY 2 TRIAL.
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Julia Dianne Wulfkuhle, Denise M. Wolf, Christina Yau, Rosa Isela Gallagher, Lamorna Brown Swigart, Gillian L. Hirst, Douglas Yee, Paula Raffin Pohlmann, Anthony D. Elias, Stacy L. Moulder, Debu Tripathy, Angela DeMichele, Laura Esserman, Donald A. Berry, Laura van 't Veer, Emanuel Petricoin, I-SPY 2 Investigators
Institutions: George Mason University, University of California, San Francisco, Buck Institute for Research on Aging, University of Minnesota, Masonic Cancer Center, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, University of Colorado Cancer Center, The University of Texas MD Anderson Cancer Center, Abramson Cancer Center, University of Pennsylvania
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2947416754